InsightfulValue
← Home

Astellas Pharma
Astellas Pharma

Pharma / Pharmaceuticals, Healthcare


Press Releases

Date Press release
2025-03-24 11:48:00 Singlera Genomics Presented Non-invasive Testicular Toxicity Detection With Astellas At 2025 Sot Meeting
San diego, march 24, 2025 (globe newswire) -- singlera genomics presented results showing a refined approach to detect drug-induced testicular toxicity using singlera’s cell-free dna methylation technology with astellas during the sot 2025 annual meeting.
2025-02-27 10:00:00 Astellas And Mbc Biolabs Announce The Sixth Annual Astellas Future Innovator Prize
Awardees win a year of access to a prestigious life-science incubator in san francisco and to astellas expertise to further their research award helps biotech start-ups accelerate early drug discovery and research efforts northbrook, ill. , feb. 27, 2025 /prnewswire/ -- astellas pharma u.s. inc. (head of commercial: mike petroutsas, \"astellas\"), and mbc biolabs, a premier launchpad for early-stage life-science companies, today announced their collaboration on the astellas future innovator prize.
2025-02-12 18:32:00 U.s. Fda Approves Expanded Label For Astellas’ Izervay™ (avacincaptad Pegol Intravitreal Solution) For Geographic Atrophy
Izervay dosing approved beyond 12 months  tokyo , feb. 12, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, \"astellas\") today announced the u.s. food and drug administration (fda) approved expanded u.s. prescribing information for izervay™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (ga) secondary to age-related macular degeneration (amd). as a result, izervay is now approved without a limitation on duration of dosing—providing physicians and patients with greater flexibility when managing ga.
2025-02-05 03:59:00 Astellas Submits New Drug Application For Conditional Approval Of Avacincaptad Pegol For Geographic Atrophy In Japan
- ministry of health, labour and welfare to evaluate acp as potential first and only treatment for patients with geographic atrophy (ga) secondary to age-related macular degeneration (amd) in japan - tokyo , feb. 5, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503) (president and ceo: naoki okamura, \"astellas\") today announced the submission of a new drug application (nda) to japan’s ministry of health, labour and welfare (mhlw) for conditional approval of avacincaptad pegol intravitreal solution (acp), a synthetic aptamer that inhibits the complement c5 protein, for the treatment of ga secondary to amd. if approved, acp has the potential to become the first and only ga treatment available in japan.
2025-02-04 01:30:00 Astellas Makes Announcement About Management Structure
Tokyo , feb. 4, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, \"astellas\") today announced that the following changes to its management structure effective april 1, 2025. regarding the change s in management structure astellas aims to create and deliver \"value\" for patients.
2024-12-25 20:30:00 QXhjZWxlYWQgRGRwIEVu dGVycyBJbnRvIERydWcg RGlzY292ZXJ5IFNlcnZp Y2UgQWdyZWVtZW50IFdp dGggQXN0ZWxsYXMgRm9y IFRhcmdldGVkIFByb3Rl aW4gRGVncmFkZXJz
VG9reW8tLShidXNpbmVz cyB3aXJlKS0tICNhc3Rl bGxhcy0tYXhjZWxlYWQg ZGRwIGVudGVycyBpbnRv IGRydWcgZGlzY292ZXJ5 IHNlcnZpY2UgYWdyZWVt ZW50IHdpdGggYXN0ZWxs YXMgZm9yIHRhcmdldGVk IHByb3RlaW4gZGVncmFk ZXJzLg==
2024-12-05 08:49:00 QXN0ZWxsYXMgQW5kIERy LiBKZW4gQXNodG9uIExh dW5jaCBcImNvb2xlciBN b21lbnRzXCIgVG8gU3Bv dGxpZ2h0IE1lbm9wYXVz YWwgSG90IEZsYXNoZXMg QW5kIEVtcG93ZXIgV29t ZW4gVG8gQWR2b2NhdGUg Rm9yIFRoZW1zZWx2ZXM=
XCJjb29sZXIgbW9tZW50 c1wiIGVkdWNhdGVzIGFu ZCBlbXBvd2VycyB3b21l biBpbiBtaWRsaWZlIHRv IHNwZWFrIHVwIGZvciB0 aGVtc2VsdmVzIGFuZCBj ZWxlYnJhdGUgdGhpcyBu YXR1cmFsIGNoYW5nZSBp biB0aGVpciBsaXZlcy4g bm9ydGhicm9vaywgaWxs Lg==
2024-11-20 13:00:00 QXN0ZWxsYXMgQW5ub3Vu Y2VzIERlc2VydCBPYXNp cyBIZWFsdGhjYXJlIEFz IEZpcnN0IEhlYWx0aCBT eXN0ZW0gVG8gSW1wbGVt ZW50IERpZ2l0aXZh4oSi IEZvciBIZWFydCBGYWls dXJlIE1hbmFnZW1lbnQ=
U2FuIGZyYW5jaXNjbyAs IG5vdi4gMjAsIDIwMjQg L3BybmV3c3dpcmUvIC0t IGFzdGVsbGFzIHBoYXJt YSB1LnMuLCBpbmMuIChw cmVzaWRlbnQ6IG1pa2Ug cGV0cm91dHNhcywgXCJh c3RlbGxhc1wiKSB0b2Rh eSBhbm5vdW5jZWQgdGhh dCBpdCBoYXMgZW50ZXJl ZCBpbnRvIGFuIGFncmVl bWVudCB3aXRoIGRlc2Vy dCBvYXNpcyBoZWFsdGhj YXJlIChkb2hjKSwgYSBt ZW1iZXIgb2YgaGVyaXRh Z2UgcHJvdmlkZXIgbmV0 d29yayzCoHRvIHBpbG90 IGRpZ2l0aXZh4oSiLCBh IG5vbi1pbnZhc2l2ZSBk aWdpdGFsIGhlYWx0aCBz b2x1dGlvbiBmb3IgdGhl IG1hbmFnZW1lbnQgb2Yg aGVhcnQgZmFpbHVyZSBw YXRpZW50cy4gaW4gdGhl IG5leHQgZmV3IHdlZWtz LCBlbGlnaWJsZSBwYXRp ZW50cyByZWNlaXZpbmcg Y2FyZSB3aXRowqBkb2hj wqB3aWxsIGJlZ2luIHVz aW5nIGRpZ2l0aXZhIGFz IGEgbmV3IG1ldGhvZCBm b3IgbWFuYWdpbmcgdGhl aXIgaGVhcnQgaGVhbHRo IHdoaWxlIHdvcmtpbmcg aW4gcGFydG5lcnNoaXAg d2l0aCB0aGVpciBoZWFs dGhjYXJlIHRlYW0u
2024-10-10 03:00:00 QXN0ZWxsYXMgVG8gUHJl c2VudCBWZW96YeKEoiAo ZmV6b2xpbmV0YW50KSBE YXRhIEF0IEltcyBXb3Js ZCBDb25ncmVzcyBPbiBN ZW5vcGF1c2U=
VG9reW8gLCBvY3QuIDEw LCAyMDI0IC9wcm5ld3N3 aXJlLyAtLcKgYXN0ZWxs YXMgcGhhcm1hIGluYy4g KHRzZTogNDUwMywgcHJl c2lkZW50IGFuZCBjZW86 IG5hb2tpIG9rYW11cmEs IFwiYXN0ZWxsYXNcIikg YW5ub3VuY2VkIHRoYXQg dmVvemHihKLCoChmZXpv bGluZXRhbnQpKiwgaXRz IGZpcnN0LWluLWNsYXNz IHRyZWF0bWVudCBmb3Ig bW9kZXJhdGUgdG8gc2V2 ZXJlIHZhc29tb3RvciBz eW1wdG9tcyAodm1zKSBh c3NvY2lhdGVkIHdpdGgg bWVub3BhdXNlLCB3aWxs IGJlIGZlYXR1cmVkIGlu IGZvdXIgb3JhbCBhbmQg dHdvIHBvc3RlciBwcmVz ZW50YXRpb25zIGR1cmlu ZyB0aGUgaW50ZXJuYXRp b25hbCBtZW5vcGF1c2Ug c29jaWV0eSAoaW1zKSAx OXRoIHdvcmxkIGNvbmdy ZXNzIG9uIG1lbm9wYXVz ZSBpbiBtZWxib3VybmUs IGF1c3RyYWxpYSwgb2N0 b2JlciAxOS0yMi4gdm1z LCBhbHNvIGtub3duIGFz IGhvdCBmbGFzaGVzIGFu ZC9vciBuaWdodCBzd2Vh dHMsIGFyZSBjb21tb24g c3ltcHRvbXMgb2YgbWVu b3BhdXNlLg==
2024-10-08 09:27:00 QXN0ZWxsYXMgQW5kIEF2 aWFkb2JpbyBBbm5vdW5j ZSBFeGNsdXNpdmUgT3B0 aW9uIEFuZCBMaWNlbnNl IEFncmVlbWVudCBGb3Ig R2VuZSBUaGVyYXB5IEF2 Yi0xMDEgVGFyZ2V0aW5n IEZyb250b3RlbXBvcmFs IERlbWVudGlhIEFuZCBP dGhlciBJbmRpY2F0aW9u cw==
QXN0ZWxsYXMgcmVjZWl2 ZXMgYW4gZXhjbHVzaXZl IG9wdGlvbiB0byBsaWNl bnNlIGF2Yi0xMDEsIGFu IGludmVzdGlnYXRpb25h bCwgYWF2LWJhc2VkIGdl bmUgdGhlcmFweSBpbiBw aGFzZSAxLzIgZGV2ZWxv cG1lbnTCoCBhdmlhZG9i aW8gcmVjZWl2ZXMgJDIw IG1pbGxpb24gZXF1aXR5 IGludmVzdG1lbnQsIHVw IHRvICQzMCBtaWxsaW9u IGluIHVwZnJvbnQgcGF5 bWVudHMgYW5kIGlzIGVs aWdpYmxlIHRvIHJlY2Vp dmUgdXAgdG8gJDIuMTgg YmlsbGlvbiBpbiBsaWNl bnNlIGZlZXMgYW5kIG1p bGVzdG9uZSBwYXltZW50 cyBwbHVzIHJveWFsdGll cyBpZiBhc3RlbGxhcyBl eGVyY2lzZXMgaXRzIG9w dGlvbiBsb25kb24gYW5k IHRva3lvICwgb2N0LiA4 LCAyMDI0IC9wcm5ld3N3 aXJlLyAtLSBhdmlhZG9i aW8gbHRkLiAoXCJhdmlh ZG9iaW9cIikgYW5kIGFz dGVsbGFzIHBoYXJtYSBp bmMuICh0c2U6IDQ1MDMs IHByZXNpZGVudCBhbmQg Y2VvOiBuYW9raSBva2Ft dXJhLCBcImFzdGVsbGFz XCIpIHRvZGF5IGFubm91 bmNlZCBhbiBleGNsdXNp dmUgb3B0aW9uIGFuZCBs aWNlbnNlIGFncmVlbWVu dCBmb3IgYXZiLTEwMSwg YW4gaW52ZXN0aWdhdGlv bmFsLCBhYXYtYmFzZWQg Z2VuZSB0aGVyYXB5IGlu IHBoYXNlIDEvMiBkZXZl bG9wbWVudCBmb3IgcGF0 aWVudHMgd2l0aCBmcm9u dG90ZW1wb3JhbCBkZW1l bnRpYSB3aXRoIHByb2dy YW51bGluIG11dGF0aW9u cyAoZnRkLWdybiku
2024-10-01 16:24:00 U2luZ2xlcmEgR2Vub21p Y3MgQW5kIEFzdGVsbGFz IFByZXNlbnQgTWV0aHls YXRpb24tYmFzZWQgT3Jn YW4gVG94aWNpdHkgRGV0 ZWN0aW9uIEF0IDIwMjQg SnNvdCBBbm51YWwgTWVl dGluZw==
U2FuIGRpZWdvLS0oYnVz aW5lc3Mgd2lyZSktLXNp bmdsZXJhIGdlbm9taWNz IGFuZCBhc3RlbGxhcyBw aGFybWEgcHJlc2VudGVk IHJlc3VsdHMgZHVyaW5n IHRoZSBqc290IDIwMjQg YW5udWFsIG1lZXRpbmcg ZGVtb25zdHJhdGluZyB0 aGF0IGRydWctaW5kdWNl ZCB0ZXN0aWN1bGFyIHRv eGljaXR5IGNhbiBiZSBk ZXRlY3RlZCB1c2luZyBj ZWxsLWZyZWUgZG5hIG1l dGh5bGF0aW9uIGluIGFu aW1hbCBtb2RlbHMuIHNp bmdsZXJh4oCZcyBtdGl0 YW4gdGVjaG5vbG9neSBo YXMgcHJldmlvdXNseSBi ZWVuIHV0aWxpemVkIHRv IG5vbi1pbnZhc2l2ZWx5 IGRldGVjdCBjYW5jZXIg bWV0aHlsYXRpb24gc2ln bmFscyBpbiBibG9vZCBm b3VyIHllYXJzIHByaW9y IHRvIHBhdGllbnRzIHNo b3dpbmcgc3ltcHRvbXMu IGFzdGVsbGFzIHByZXNl bnRlZCB0aGUgcmVzdWx0 cyBvZiBhbmltYWwgbW9k ZWwgZXhwZXJpbWVudHMg ZGVtb25zdHJhdGluZyB0 aGF0IHRoZXNlIHRlY2hu b2xvZ2llLg==
2024-09-20 09:17:00 QXN0ZWxsYXMgUmVjZWl2 ZXMgQXBwcm92YWwgRnJv bSBUaGUgRXVyb3BlYW4g Q29tbWlzc2lvbiBGb3Ig Vnlsb3nihKIgKHpvbGJl dHV4aW1hYikgSW4gQ29t YmluYXRpb24gV2l0aCBD aGVtb3RoZXJhcHkgRm9y IEFkdmFuY2VkIEdhc3Ry aWMgQW5kIEdhc3Ryb2Vz b3BoYWdlYWwgSnVuY3Rp b24gQ2FuY2Vy
LSB6b2xiZXR1eGltYWIg aXMgY3VycmVudGx5IHRo ZSBmaXJzdCBhbmQgb25s eSB0aGVyYXB5IGFwcHJv dmVkIGluIHRoZSBldXJv cGVhbiB1bmlvbiB0b8Kg dGFyZ2V0IGNsYXVkaW4g MTguMiwgYSBiaW9tYXJr ZXIgcG9zaXRpdmVseSBl eHByZXNzZWQgYnkgMzgl IG9mIHBhdGllbnRzIHdp dGggYWR2YW5jZWQgZ2Fz dHJpYyBjYW5jZXIxLDIg LSB0cmVhdG1lbnQgd2l0 aCB0aGUgY2xhdWRpbiAx OC4yLXRhcmdldGVkIG1v bm9jbG9uYWwgYW50aWJv ZHkgc2hvd24gdG8gc2ln bmlmaWNhbnRseSBleHRl bmQgYm90aCBwcm9ncmVz c2lvbi1mcmVlIHN1cnZp dmFsIGFuZCBvdmVyYWxs IHN1cnZpdmFsIGluIHBo YXNlIDMgdHJpYWxzMSwg MiB0b2t5byAsIHNlcHQu IDIwLCAyMDI0IC9wcm5l d3N3aXJlLyAtLSBhc3Rl bGxhcyBwaGFybWEgaW5j LiAodHNlOiA0NTAzLCBw cmVzaWRlbnQgYW5kIGNl bzogbmFva2kgb2thbXVy YSwgXCJhc3RlbGxhc1wi KSB0b2RheSBhbm5vdW5j ZWQgdGhhdCB0aGUgZXVy b3BlYW4gY29tbWlzc2lv biAoZWMpIGhhcyBhcHBy b3ZlZCB2eWxveeKEoiAo em9sYmV0dXhpbWFiKSBp biBjb21iaW5hdGlvbiB3 aXRoIGZsdW9yb3B5cmlt aWRpbmUtIGFuZCBwbGF0 aW51bS1jb250YWluaW5n IGNoZW1vdGhlcmFweSBm b3IgdGhlIGZpcnN0LWxp bmUgdHJlYXRtZW50IG9m IGFkdWx0IHBhdGllbnRz IHdpdGggbG9jYWxseSBh ZHZhbmNlZCB1bnJlc2Vj dGFibGUgb3IgbWV0YXN0 YXRpYyBodW1hbiBlcGlk ZXJtYWwgZ3Jvd3RoIGZh Y3RvciByZWNlcHRvciAy IChoZXIyKS1uZWdhdGl2 ZSBnYXN0cmljIG9yIGdh c3Ryb2Vzb3BoYWdlYWwg anVuY3Rpb24gKGdlaikg YWRlbm9jYXJjaW5vbWEg d2hvc2UgdHVtb3JzIGFy ZSBjbGF1ZGluIChjbGRu KSAxOC4yIHBvc2l0aXZl Lg==
2024-09-18 19:30:00 QXN0ZWxsYXMgQW5ub3Vu Y2VzIEZkYSBMaXN0aW5n IE9mIERpZ2l0aXZh4oSi IEZvciBUaGUgTWFuYWdl bWVudCBPZiBIZWFydCBG YWlsdXJl
LSBuZXcgZGlnaXRhbCBo ZWFsdGggc29sdXRpb24g Zm9yIGhlYXJ0IGZhaWx1 cmUgbWFuYWdlbWVudCBw dXRzIHBhdGllbnRzIGF0 IHRoZSBjZW50ZXIgb2Yg dGhlaXIgY2FyZSBieSBw cm92aWRpbmcgYWJpbGl0 eSBmb3IgYXQtaG9tZSBk aXNlYXNlIG1vbml0b3Jp bmcgLSB0b2t5byAsIHNl cHQuIDE4LCAyMDI0IC9w cm5ld3N3aXJlLyAtLSBh c3RlbGxhcyBwaGFybWEg aW5jLiAodHNlOiA0NTAz LCBwcmVzaWRlbnQgYW5k IGNlbzogbmFva2kgb2th bXVyYSwgXCJhc3RlbGxh c1wiKSB0b2RheSBhbm5v dW5jZWQgdGhhdCBkaWdp dGl2YeKEoiwgYSBub24t aW52YXNpdmUgZGlnaXRh bCBoZWFsdGggc29sdXRp b24gZm9yIGhlYXJ0IGZh aWx1cmUgbWFuYWdlbWVu dCwgaGFzIGJlZW4gbGlz dGVkIHdpdGggdGhlIHUu cy4gZm9vZCBhbmQgZHJ1 ZyBhZG1pbmlzdHJhdGlv biAoZmRhKS4=
2024-09-11 02:00:00 QXN0ZWxsYXMgUHJlc2Vu dHMgU2NpZW50aWZpYyBQ cm9ncmVzcyBJbiBBZHZh bmNlZCBBbmQgSGFyZC10 by10cmVhdCBDYW5jZXJz IEF0IEVzbW8gMjAyNA==
LSBlaWdodCBhYnN0cmFj dHMsIGluY2x1ZGluZyB0 d28gb3JhbCBwcmVzZW50 YXRpb25zLCBmZWF0dXJl IG5ldyBjbGluaWNhbCBk YXRhIGZyb20gYXN0ZWxs YXPigJkgb25jb2xvZ3kg cG9ydGZvbGlvIGFuZCB0 d28gbGVhZCBwaXBlbGlu ZSBwcm9ncmFtcyBhY3Jv c3MgYSBicm9hZCByYW5n ZSBvZiBjYW5jZXIgdHlw ZXMgLSB0b2t5byAsIHNl cHQuIDExLCAyMDI0IC9w cm5ld3N3aXJlLyAtLSBh c3RlbGxhc8KgcGhhcm1h IGluYy4gKHRzZTogNDUw MywgcHJlc2lkZW50IGFu ZCBjZW86IG5hb2tpIG9r YW11cmEsIFwiYXN0ZWxs YXNcIikgd2lsbCBoaWdo bGlnaHQgbmV3IGRhdGEg ZnJvbSBhY3Jvc3MgaXRz IGFwcHJvdmVkIGFuZCBp bnZlc3RpZ2F0aW9uYWwg Y2FuY2VyIHRoZXJhcGll cyBkdXJpbmcgdGhlIDIw MjQgZXVyb3BlYW4gc29j aWV0eSBmb3IgbWVkaWNh bCBvbmNvbG9neSAoZXNt bykgY29uZ3Jlc3MgYmVp bmcgaGVsZCBpbiBiYXJj ZWxvbmEsIHNwYWluIG9u IDEzLTE3IHNlcHRlbWJl ci4=
2024-09-05 10:00:00 QXN0ZWxsYXMgVW52ZWls cyBOZXcgTGlmZSBTY2ll bmNlcyBDZW50ZXIgSW4g Q2FtYnJpZGdlLCBNYXNz YWNodXNldHRzIFRvIEFj Y2VsZXJhdGUgVGhlIERp c2NvdmVyeSBPZiBCcmVh a3Rocm91Z2ggVGhlcmFw aWVz
VGhlIGFzdGVsbGFzIGxp ZmUgc2NpZW5jZXMgY2Vu dGVyIGhvc3RzIHRoZSBj b21wYW554oCZcyBmaXJz dCB1LnMuLWJhc2VkIG9w ZW4gaW5ub3ZhdGlvbiBz YWt1bGFi4oSiIGluY3Vi YXRvciBzcGFjZSBkZWRp Y2F0ZWQgdG8gZm9zdGVy aW5nIHBpb25lZXJpbmcg c2NpZW5jZSB0aHJvdWdo IGNvbGxhYm9yYXRpb24g d2l0aCBleHRlcm5hbCBw YXJ0bmVycyB0b2t5byBh bmQgY2FtYnJpZGdlLCBt YXNzLiAsIHNlcHQuIDUs IDIwMjQgL3BybmV3c3dp cmUvIC0twqB0b2RheSwg YXN0ZWxsYXMgcGhhcm1h IGluYy4gKHRzZTogNDUw MywgcHJlc2lkZW50IGFu ZCBjZW86IG5hb2tpIG9r YW11cmEsIFwiYXN0ZWxs YXNcIikgb2ZmaWNpYWxs eSBvcGVuZWQgaXRzIG5l dyBhc3RlbGxhcyBsaWZl IHNjaWVuY2VzIGNlbnRl ciAoYWxzYykgaW4gY2Ft YnJpZGdlLCBtYXNzLg==
Astellas Pharma

Browse additional press releases for Astellas Pharma!

Sign up for free or log in
© 2024 - 2025 InsightfulValue.com. All rights reserved. Legal